Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944944 · ClinicalTrials.gov registry record
Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 58
- Enrollment target
NCT00944944: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00944944 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00944944 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) truly detects symptoms or signs of lower extremity lymphedema in patients with diagnosed lower extremity lymphedema. Lymphedema is a chronic condition in which fluid accumulates in the tissues of the body. Many cancer survivors are living with discomfort and changes in their activities due to limb swelling following cancer treatment. If the GCLQ is able to do detect signs and symptoms of lymphedema, the investigators hope to use it as a tool in the clinical care setting to help identify women at risk for or with lymphedema. In the future, this could improve clinical care through the use of a more simple and feasible way to identify lower extremity lymphedema than measuring limbs.
Interventions
- BEHAVIORAL limb volume measurements and GCLQ lymphedema symptom assessment questionnaire
- BEHAVIORAL GCLQ lymphedema symptom assessment questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-01 |
What the finished NCT00944944 record still lists
NCT00944944 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which limb volume measurements and GCLQ lymphedema symptom assessment questionnaire is the first listed.
NCT00944944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00944944 about?
NCT00944944 is a clinical study titled "Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema". The purpose of this study is to evaluate if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) truly detects symptoms or signs of lower extremity lymphedema in patients with diagnosed lower extremity lymphedema. Lymphedema is a chronic condition in which fluid accumulates in the tissues of the b...
What is the current status of trial NCT00944944?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2009-07. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00944944?
The interventions under investigation include: limb volume measurements and GCLQ lymphedema symptom assessment questionnaire (BEHAVIORAL), GCLQ lymphedema symptom assessment questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT00944944?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia